Sucampo Pharmaceuticals, Inc. (SCMP) Lifted to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) from a sell rating to a hold rating in a report released on Tuesday morning.
According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating into new markets. Also, the company’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. The company has lowered its earnings outlook to include the Vtesee acquisition. Shares of the company have underperformed the industry.”
SCMP has been the subject of a number of other research reports. ValuEngine upgraded Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, June 23rd. Leerink Swann started coverage on Sucampo Pharmaceuticals in a report on Monday, August 21st. They set an outperform rating and a $15.00 price objective for the company. Roth Capital set a $30.00 price objective on Sucampo Pharmaceuticals and gave the company a buy rating in a report on Thursday, August 3rd. Maxim Group restated a buy rating and set a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Finally, TheStreet cut Sucampo Pharmaceuticals from a c+ rating to a d rating in a report on Wednesday, August 2nd. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $17.86.
Sucampo Pharmaceuticals (SCMP) traded down 0.237% during mid-day trading on Tuesday, hitting $10.525. The stock had a trading volume of 1,045,034 shares. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55. The stock’s 50-day moving average price is $11.69 and its 200-day moving average price is $10.73. The stock’s market cap is $487.57 million.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same quarter in the previous year, the business earned $0.24 EPS. Sucampo Pharmaceuticals’s revenue was up 15.3% compared to the same quarter last year. On average, analysts predict that Sucampo Pharmaceuticals will post $1.01 earnings per share for the current year.
WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Lifted to “Hold” at Zacks Investment Research” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/sucampo-pharmaceuticals-inc-scmp-lifted-to-hold-at-zacks-investment-research.html.
In other news, insider Jason Patrick Meyenburg bought 4,000 shares of the stock in a transaction on Wednesday, September 6th. The stock was acquired at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the acquisition, the insider now owns 30,228 shares of the company’s stock, valued at $366,665.64. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jones W. Bryan bought 4,700 shares of the stock in a transaction on Friday, August 4th. The stock was purchased at an average price of $10.60 per share, with a total value of $49,820.00. Following the completion of the acquisition, the insider now directly owns 4,700 shares in the company, valued at approximately $49,820. The disclosure for this purchase can be found here. 4.13% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the business. Krensavage Asset Management LLC lifted its holdings in shares of Sucampo Pharmaceuticals by 0.6% in the 2nd quarter. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company’s stock worth $29,607,000 after buying an additional 16,570 shares during the period. LSV Asset Management lifted its holdings in shares of Sucampo Pharmaceuticals by 1.9% in the 2nd quarter. LSV Asset Management now owns 2,390,418 shares of the biopharmaceutical company’s stock worth $25,099,000 after buying an additional 44,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Sucampo Pharmaceuticals by 13.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after buying an additional 189,561 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after buying an additional 15,528 shares during the period. Finally, NEA Management Company LLC purchased a new stake in shares of Sucampo Pharmaceuticals in the 2nd quarter worth $13,214,000. Institutional investors and hedge funds own 55.44% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.